Literature DB >> 18497518

Mitomycin C in the treatment of gastrointestinal tumours: recent data and perspectives.

Ralf-Dieter Hofheinz1, Ulrich Beyer, Salah-Eddin Al-Batran, Jörg Thomas Hartmann.   

Abstract

Mitomycin C (MMC) is among the most effective anticancer drugs used for the treatment of a broad variety of tumours. This review summarises results of MMC-based chemotherapy in gastrointestinal tumours with special focus on current treatment options in gastric, pancreatic, biliary tract, colorectal, and anal cancer. In addition, these new developments are critically discussed with special attention to their potential clinical relevance. (c) 2008 S. Karger AG, Basel

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18497518     DOI： 10.1159/000122590

Source DB:  PubMed          Journal:  Onkologie        ISSN： 0378-584X


  10 in total

1.  Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells.

Authors:  Pei-Chih Lee; Rajesh Kakadiya; Tsann-Long Su; Te-Chang Lee
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

Review 2.  Using synthetic DNA interstrand crosslinks to elucidate repair pathways and identify new therapeutic targets for cancer chemotherapy.

Authors:  Angelo Guainazzi; Orlando D Schärer
Journal:  Cell Mol Life Sci       Date:  2010-08-21       Impact factor: 9.261

3.  In vitro and in vivo antimutagenic effects of DIG, a herbal preparation of Berberis vulgaris, Taraxacum officinale and Arctium lappa, against mitomycin C.

Authors:  C Di Giorgio; L Boyer; M De Meo; C Laurant; R Elias; E Ollivier
Journal:  J Nat Med       Date:  2015-02-10       Impact factor: 2.343

4.  An integrated microfluidic cell array for apoptosis and proliferation analysis induction of breast cancer cells.

Authors:  Huixue Song; Tan Chen; Baoyue Zhang; Yifan Ma; Zhanhui Wang
Journal:  Biomicrofluidics       Date:  2010-10-08       Impact factor: 2.800

5.  Membrane sphingolipids as essential molecular signals for Bacteroides survival in the intestine.

Authors:  Dingding An; Chongzheng Na; Jacek Bielawski; Yusuf A Hannun; Dennis L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-20       Impact factor: 11.205

6.  Liver sinusoidal endothelial and biliary cell repopulation following irradiation and partial hepatectomy.

Authors:  Petra Krause; Margret Rave-Fränk; Hendrik Andreas Wolff; Heinz Becker; Hans Christiansen; Sarah Koenig
Journal:  World J Gastroenterol       Date:  2010-08-21       Impact factor: 5.742

7.  Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C - an experimental study.

Authors:  Olaf Sørensen; Anders Andersen; Harald Olsen; Kristian Alexandr; Per Olaf Ekstrøm; Karl-Erik Giercksky; Kjersti Flatmark
Journal:  BMC Cancer       Date:  2010-09-01       Impact factor: 4.430

8.  A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies.

Authors:  Tanios Bekaii-Saab; Marisa Hill; Angela Campbell; Kavitha Kosuri; James Thomas; Miguel Villalona-Calero
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-06       Impact factor: 3.333

9.  Mitomycin C Inhibits Esophageal Fibrosis by Regulating Cell Apoptosis and Autophagy via lncRNA-ATB and miR-200b.

Authors:  Yin Zhang; Qinge Wang; Yuping Xu; Jing Sun; Yanbo Ding; Li Wang; Bingfang Chen; Kewen Sun; Jianping Chen
Journal:  Front Mol Biosci       Date:  2021-05-17

10.  Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma.

Authors:  Dominique Werner; Akin Atmaca; Claudia Pauligk; Anette Pustowka; Elke Jäger; Salah-Eddin Al-Batran
Journal:  Cancer Med       Date:  2013-04-02       Impact factor: 4.452
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.